Emergex Vaccines: Emergex inks pact with DEKA to assess compatibility of Emergex's immunotherapeutic candidates with DEKA's intradermal therapeutic applicator
Emergex Vaccines Holding Limited (Emergex), a clinical─stage biotechnology company addressing major global infectious diseases through the development of synthetic T cell─priming set─point immunotherapy─based treatment
Read full article »
Emergex is an England-based biotechnology company that develops and commercializes T-cell vaccines for the treatment of viral and bacterial infectious diseases.
Read more